Cellectis and Weill Cornell Collaborate to Develop New Leukaemia Immunotherapies

Cellectis, a French biopharmaceutical firm, has entered into a translational research collaboration with Weill Cornell Medical College situated in the US. The alliance will aim to fast-track development of a targeted immunotherapy for patients with acute myelogenous leukaemia (AML). The partnership will be combining Cellectis’ work in the development and manufacture of gene edited CAR

Continue Reading